Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate

You may also be interested in...



Complete Submissions Are Key To Good Review Management Principles – FDA

As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process

Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate

Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.

Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate

Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.

Related Content

Topics

UsernamePublicRestriction

Register

PS003005

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel